Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.</li>
<li>The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.</li>
<li>The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.</li>
</ul>


Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.
The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.
The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.


Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Symbiotec Pharmalab / Equity Capital Markets

<ul>
<li>Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.</li>
<li>The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).</li>
<li>The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.</li>
</ul>


Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.
The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).
The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.


Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/symbiotec-pharmalab-ltd" target="_blank" data-smartkarma-citation="entities:46311:1" rel="noopener">Symbiotec Pharmalab Ltd (971073Z IN)</a> is looking to raise about US$244m in its upcoming India IPO. The deal will be run by Avendus, JM Fin, Nomura and Motilal Oswal.</li>
<li>SPL is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables.</li>
<li>According to the Frost &amp; Sullivan report, SPL had a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients in volume terms in FY25.</li>
</ul>



Symbiotec Pharmalab Ltd (971073Z IN) is looking to raise about US$244m in its upcoming India IPO. The deal will be run by Avendus, JM Fin, Nomura and Motilal Oswal.
SPL is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables.
According to the Frost &amp; Sullivan report, SPL had a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients in volume terms in FY25.


Aequitas: Symbiotec Pharmalab Ltd Pre-IPO Tearsheet

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, a number of ~US$1bn deals could launch this week.</li>
<li>On the placement front, flow continues to slowdown going into year end earnings season.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, a number of ~US$1bn deals could launch this week.
On the placement front, flow continues to slowdown going into year end earnings season.


Aequitas ECM Weekly (26 January 2026)- Busy Ming, Montage, Eastroc, Muyuan, Longcheer, Sinotruk,

India

Symbiotec Pharmalab Limited operates as a research-driven science-based pharmaceutical and biotechnology company. The Company manufactures corticosteroid and steroidal hormone active pharmaceutical ingredients. Symbiotec Pharmalab serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Symbiotec Pharmalab (SYMBIOTE IN)

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Symbiotec Pharmalab combines leadership in steroidal APIs with complex injectables and biotech capabilities, offering global growth opportunities...

Nimish Maheshwari

Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

Symbiotec Pharmalab launches India IPO consisting of fresh issue of INR2B and OFS of INR16B. The price band is set at INR938–988. The IPO proceeds...

Tina Banerjee

Aequitas: Symbiotec Pharmalab Ltd Pre-IPO Tearsheet

Symbiotec Pharmalab Ltd (SPL) is looking to raise about US$244m in its upcoming India IPO. The deal will be run by Avendus, JM Fin, Nomura and...

Akshat Shah

Aequitas ECM Weekly (26 January 2026)- Busy Ming, Montage, Eastroc, Muyuan, Longcheer, Sinotruk,

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)